Biosimilar Drugs
Tóm tắt
Patents for biologic agents first marketed in the 1980s are now beginning to expire, opening the door for ‘nonproprietary’ versions of these agents to enter the market. However, there are fundamental differences between biologics and traditional pharmaceuticals that preclude the extrapolation of existing regulatory processes for traditional generic agents to these new biologic products. These include differences in dimensions (molecular weight), synthesis, purification, stability, and immunogenicity. There is also controversy over the terminology of these biologic agents, with a number of terms put forward. European regulatory authorities have adopted the term ‘biosimilars,’ while the US FDA prefers the term ‘follow-on biologics.’ It is important that these terms are not used as synonyms for ‘generics,’ and already there are moves to prevent classification of these products as ‘generics.’ In this review, we focus on the differences that exist between generics and biosimilars, and assess the current scenario of problems and opportunities. Furthermore, we also attempt to highlight the problems with establishing regulatory guidelines and those associated with the introduction of these drugs into clinical practice.
Tài liệu tham khảo
Belsey MJ, Harris LM, Das RR, et al. Biosimilars: initial excitement gives way to reality. Nat Rev Drug Discov 2006; 5 (7): 535–6
Lewcock A. French law disallow ‘generic’ biosimilars. In-pharma Technologist. com. 2007 Feb [online]. Available from URL: http://www.in-pharmatechnologist.com/news [Accessed 2007 Apr 2]
F. Hoffmann-La Roche Ltd. Roche position on similar biological medicinal products. 2005 Mar [online]. Available from URL: http://www.roche.com/sus_polsimilb.pdf[Accessed 2007 Apr 2]
Ronco C. Biosimilars: how similar are they? Int J Artif Organs 2005 Jun; 28 (6): 552–3
Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002 Jun; 1 (6): 457–62
European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). CHMP temporary working parties. EMEA 2005 Oct [online]. Available from URL: http://www.emea.europa.eu/htms/general/contacts/CHMP/CHMP_BMWP.html [Accessed 2007 Apr 2]
Pavlou AK. The market of therapeutic recombinant proteins to 2010. J Commerc Biotechnol 2004 Jun; 10 (4): 363–7
Griffiths S. Betting on biogenerics. Nat Rev Drug Discov 2004 Mar; 3 (3): 197–8
European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA 2003 Dec [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/309702en.pdf[Accessed 2007 Apr 2]
European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. EMEA Evaluation of Medicines for Human Use. 2005 Oct [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf[Accessed 2007 Apr 2]
Grabowski H, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff 2006; 25 (5): 1291–301
US Committee on Oversight and Government Reform. Hearing examines safe and affordable generic biotech drugs. Hearing 2007 Mar 26 [online]. Available from URL: http://oversight.house.gov/story.asp?ID=1223[Accessed 2007 Oct 31]
Reuters Health News. Complex generic biologics need more data: FDA. 2007 Mar 26 [online]. Available from URL: http://today.reuters.com/news/articlenews.aspx?.type=healthNews&storyid=2007-03-26T184805Z_01_N26343231_R-TRUKOC_0_US-CONGRESS-BIOLOGICS.xml [Accessed 2007 May 16]
Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001 Mar; 46 (1–3): 3–26
Schellekens H. Follow-on biologies: challenges of the ‘next generation’. Nephrol Dial Transplant 2005 May; 20 Suppl. 4: iv31–6
Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004; 3: 43–7
Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005 Jul; 25 (7): 954–62
Raines LJ. Bad medicine: why the generic drug regulatory paradigm is inapplicable to biotechnology products. J Biolaw Business 2002; 5 (1): 6–12
Brady RO. Gaucher’s disease: past, present and future. Baillieres Clin Haematol 1997 Dec; 10 (4): 621–34
Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006 Oct; 21 Suppl. 5: v9–12
Schellekens H. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity. Eur J Clin Invest 2004 Dec; 34 (12): 797–9
US Food and Drug Administration, Center for Drug Evaluation and Research. Regulatory and scientific issues related to developing follow-on protein products [online]. Available from URL: http://www.fda.gov/cder/regulatory/follow_on/default.htm[Accessed 2007 Apr 2]
Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346 (7): 469–75
Committee for Medicinal Products for Human Use (CHMP). Annex guideline on similar biological medicinal products containing biotechnology derived proteins as active substance: non-clinical and clinical issues: guidance on biosimilar medicinal products containing recombinant erythropoietins. European Medicines Agency (EMEA) [online]. Available from URL: http://www.emea.eu.int[Accessed 2007 Oct 3]
Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21 (Suppl. 5): vl3–vl6
WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortyfirst report. WHO Technical Report Series: 943 [online]. Available from URL: http://www.who.int/prequal/info_general/documents/TRS943/TRS943.pdf[Accessed 2007 Oct 31]
WHO Informal Consultation on International Nonproprietary Names (INN) policy for biosimilar products; Geneva. 2006 Sep 4-5 [online]. Available from URL: http://www.who.int/medicines/services/inn/BiosimilarsINN_Report.pdf[Accessed 2007 Aug 28]
European Generic Medicines Association. Competition and affordability in biopharmaceuticals [online]. Available from URL: http://www.egagenerics.com/ega-biosimilars.htm [Accessed 2007 Aug 28]